Autor: | Hiroyasu Ina, Tetsuya Irie, Tetsuo Yoshida, Toshihiko Wakita, Sunao Mae, Naoya Gomi, Isamu Ohashi, Yoshiro Himeno, Kazunori Kubota, Yoichi Okada |
---|---|
Rok vydání: | 2003 |
Předmět: |
medicine.medical_specialty
Chemotherapy medicine.diagnostic_test Physiology business.industry medicine.medical_treatment Gastroenterology Computed tomography Hepatology medicine.disease Resectable Hepatocellular Carcinoma Hepatocellular carcinoma Internal medicine medicine Embolization Radiology Percutaneous ethanol injection Initial therapy business |
Zdroj: | Digestive Diseases and Sciences. 48:587-593 |
ISSN: | 0163-2116 |
DOI: | 10.1023/a:1022557220624 |
Popis: | We present the survival rates of 75 nonruptured hepatocellular carcinoma cases initially treated with computed tomography-guided transarterial chemoembolization in a single institute. The 1-, 3-, and 5-year survival rates were 93.9%, 74.7%, and 47.4% in 50 Child's A cases; 75.0%, 43.6%, and 6.8% in 20 Child's B cases; and 60.0%, 40.0%, 0.0% in 5 Child's C cases, respectively. The 1-, 3-, and 5-year survival rates of the 38 estimated resectable hepatocellular carcinoma cases (Child's A, tumors limited in a single lobe) were 94.7%, 82.0%, and 44.6%, respectively. The 1-, 3-, and 5-year survival rates of the 41 cases with estimated indication for percutaneous ethanol injection therapy (tumors less than 3 cm in diameter and three or fewer in number) were 96.8%, 84.6%, and 55.5% in 31 Child's A cases; and 90.0%, 46.7%, and 0% in 10 Child's B cases, respectively. In conclusion, computed tomography-guided transarterial chemoembolization is an excellent primary therapy for hepatocellular carcinoma. |
Databáze: | OpenAIRE |
Externí odkaz: |